Abstract
Gastric cancer (GC) is one of the most common malignancies, ranking the third highest mortality rate worldwide. Due to the insidious symptoms and difficulty in early detection, patients with GS were mostly in the middle and late stages when they were diagnosed. Although ontogenetic or tumor-suppressive effects of miRNA-200a-3p have been demonstrated, the exact mechanism underlying GC is not clear. Therefore, the expression, effect, and mechanism of miRNA-200a-3p in GC progression were systematically investigated in this study. qRT-PCR, Western blotting, and immunohistochemical staining were applied to investigate the miRNA-200a-3p and deleted in liver cancer 1 (DLC-1) expression. Cell viability, proliferation, apoptosis, migration, and invasion capabilities of GC cells were assessed using cell counting kit-8 (CCK-8) colorimetry, EdU integration, flow cytometry, wound healing, and the transwell assay. The relationship between miRNA-200a-3p and tumor growth was investigated by tumor xenograft assay in vivo. A dual-luciferase reporter assay was estimated to verify the connection between miR-200-3p and DLC-1. The results showed that miRNA-200a-3p expression was significantly increased in both GC tissues and cells. Furthermore, via DLC-1, miRNA-200a-3p promotes tumor growth and development. miRNA-200a-3p, by targeting DLC-1, can function as an oncogene in GC cells. Collectively, our findings indicated that the miRNA-200a-3p/DLC axis might provide a theological basis for potential improvements in GC treatment strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A (2018) Medical management of gastric cancer: a 2017 update. Cancer Med 7(1):123–133
Chen Z, Liu X, Hu Z, Wang Y, Liu M, Liu X, Li H, Ji R, Guo Q, Zhou Y (2015) Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer. Oncol Lett 10(1):329–336
Ding M, Sun X, Zhong J, Zhang C, Tian Y, Ge J, Zhang CY, Zen K, Wang JJ, Zhang C et al (2018) Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL. J Cell Biochem 119(12):9974–9985
Hao NB, He YF, Li XQ, Wang K, Wang RL (2017) The role of miRNA and lncRNA in gastric cancer. Oncotarget 8(46):81572–81582
Link H, Angele M, Schuller M, Ganschow P, Machetanz L, Guba M, Werner J, Kirchner T, Neumann J (2018) Extra-capsular growth of lymph node metastasis correlates with poor prognosis and high SOX9 expression in gastric cancer. BMC Cancer 18(1):483
0 C, Hu W, Li LL, Wang YX, Zhou Q, Zhang F, Song-Yang YY, Zhu W, Sun CC, Li DJ (2018) Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol 14(27):2875–2886
Liu L, Ren W, Chen K (2017) MiR-34a promotes apoptosis and inhibits autophagy by targeting HMGB1 in acute myeloid leukemia cells. Cell Physiol Biochem 41(5):1981–1992
Liu L, Tian YC, Mao G, Zhang YG, Han L (2019) MiR-675 is frequently overexpressed in gastric cancer and enhances cell proliferation and invasion via targeting a potent anti-tumor gene PITX1. Cell Signal 62:109352
Peng L, Fu J, Ming Y (2018) The miR-200 family: multiple effects on gliomas. Cancer Manag Res 10:1987–1992
Shi T, Hua Q, Ma Z, Lv Q (2017) Downregulation of miR-200a-3p induced by hepatitis B Virus X (HBx) Protein promotes cell proliferation and invasion in HBV-infection-associated hepatocarcinoma. Pathol Res Pract 213(12):1464–1469
Su Y, Lin L, Zhang J, Jiang Y, Pan C, Sun L, Duan J, Liao W (2015) Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Mol Med Rep 12(4):5771–5779
Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabo A, Gyorffy B (2016) Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7(31):49322–49333
Teng Y, Su X, Zhang X, Zhang Y, Li C, Niu W, Liu C, Qu K (2016) miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations. Oncotarget 7(49):81621–81633
Ullmannova V, Popescu NC (2006) Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 29(5):1127–1132
Verma R, Agarwal AK, Sakhuja P, Sharma PC (2019) Microsatellite instability in mismatch repair and tumor suppressor genes and their expression profiling provide important targets for the development of biomarkers in gastric cancer. Gene 710:48–58
Wang J, Zhang H, Zhou X, Wang T, Zhang J, Zhu W, Zhu H, Cheng W (2018) Five serum-based miRNAs were identified as potential diagnostic biomarkers in gastric cardia adenocarcinoma. Cancer Biomark 23(2):193–203
Wei S, Wang K, Huang X, Zhao Z, Zhao Z (2019) LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol 33:2058738419859699
Wu HT, Xie CR, Lv J, Qi HQ, Wang F, Zhang S, Fang QL, Wang FQ, Lu YY, Yin ZY (2018) The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma. Lab Invest 98(8):1014–1024
Wu PP, Zhu HY, Sun XF, Chen LX, Zhou Q, Chen J (2015) MicroRNA-141 regulates the tumour suppressor DLC1 in colorectal cancer. Neoplasma 62(5):705–712
Yang YJ, Luo S, Wang LS (2019) Effects of microRNA-378 on epithelial-mesenchymal transition, migration, invasion and prognosis in gastric carcinoma by targeting BMP2. Eur Rev Med Pharmacol Sci 23(12):5176–5186
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC (1998) Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58(10):2196–2199
Zang Y, Tai Y, Wan B, Jia X (2016) miR-200a-3p promotes the proliferation of human esophageal cancer cells by post-transcriptionally regulating cytoplasmic collapsin response mediator protein-1. Int J Mol Med 38(5):1558–1564
Funding
This study was supported by the Hospital-level topic of Jiangsu Cancer Hospital (ZM202011).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
There are no conflicts of interest among the writers.
Ethical approval
All experimental processes followed the Ethics Committee of Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University. In addition, each participant signed informed consent before the study. Both methods used in studies involving human subjects have complied with the institutional study committee's ethical guidelines and the Helsinki Declaration (WMA Declaration of Helsinki, 2013).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, Z., Wang, Y., Liu, S. et al. MiR-200a-3p promotes gastric cancer progression by targeting DLC-1. J Mol Histol 53, 39–49 (2022). https://doi.org/10.1007/s10735-021-10037-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-021-10037-7